Renalytix plc cash flow statement RENXF

In Q1 of fiscal 2025, the quarter ended Sep 30, 2024, Renalytix plc used $3.8 million of cash from operations, up 59.6% from the same quarter a year earlier.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2024
Q1 FY2025
Sep 30, 2024
Q4 FY2024
Jun 30, 2024
Q3 FY2024
Mar 31, 2024
Q2 FY2024
Dec 31, 2023
Q1 FY2024
Sep 30, 2023
Operating
Depreciation and amortization
0
0
-52.8%
0
0
0
0
Stock-based compensation
1
0
-51.4%
0
0
0
1
Operating cash flow
-24
-4
+59.6%
-8
-5
-8
-10
Investing
Investing cash flow
0
0
-0
-0
0
0
Financing
Financing cash flow
11
0
+100.0%
8
4
-1
-1
Change in cash
Effect of exchange rate
0
0
+118.9%
0
-0
0
-0
Net change in cash
-13
-4
+65.1%
-0
-1
-8
-11
Ratios
Stock-based compensation to revenue
61.27%
48.66%
71.50%
71.40%
54.44%
113.94%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
RNLXY (OTC), RENXF (OTC)
Fiscal year ends
June 30
Incorporated in
United Kingdom
Headquarters
London
SEC filer status
, Emerging growth company
SEC CIK
1811115
Former names
Renalytix AI plc (until Jun 25, 2021)

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.